Healthcare · Risk & Compliance
Deploy a Governed AI Agent for Contract Review in Pharmaceuticals
We design, build, and run AI-native contract review for pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams. This page describes the engagement: scope, pricing, timeline, controls, and the KPIs we commit to.
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native contract review for pharmaceuticals is a phased engagement (Discovery 3 weeks → Build 8 weeks → Run continuous (regulated industry)) that ships a production workflow on top of CRM and medical information systems, moves review cycle time by +210% against the pharmaceuticals baseline, and is operated under risk & compliance governance from day one.
Key facts
- Industry
- Pharmaceuticals
- Use case
- Contract Review
- Intent cluster
- Risk & Compliance
- Primary KPI
- review cycle time, fallback usage, negotiation rounds, and contract leakage
- Top benchmark
- Reviewer throughput per FTE: 1.0× → 3.1× (+210%)
- Systems integrated
- CRM, medical information systems, safety databases
- Buyer
- pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams
- Risk lens
- medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails
- Engagement timeline
- Discovery 3 weeks → Build 8 weeks → Run continuous (regulated industry)
- Team size
- 2 senior delivery + 1 part-time reviewer trainer
- Discovery price
- $8k · 2-3 week sprint
- Build price
- $30k–$40k · 8-12 weeks
Primary outcome
speed up legal and commercial review while protecting standards
What we ship
clause playbook, contract review assistant, redline workflow, and fallback library
KPIs we report on
review cycle time, fallback usage, negotiation rounds, and contract leakage
Why Pharmaceuticals teams hire us for this
Pharmaceuticals buyers we talk to share a common frustration: too many AI vendor demos, too few production deployments that survive a quarterly review. AI-native contract review is the answer to that gap — every engagement we ship is designed to pass a CFO's challenge, a risk officer's review, and an operator's daily use, simultaneously.
Pharmaceuticals compliance teams routinely report that reviewing AI-generated outputs is faster than reviewing human-generated outputs — as long as the AI system surfaces the supporting evidence at the same time. That is a design choice, not a model capability.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of contract review in pharmaceuticals-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
Reviewer throughput per FTE AI pre-assembles evidence; reviewer makes the policy decision in <2 min average | 1.0× | 3.1× | +210% |
Audit-log completeness Every inference call + reviewer action captured with version metadata | 62% | 100% | +38 pts |
Time-to-attestation Quarterly attestation packs assembled from audit log; reviewer signs off in hours | 21 days | 3 days | −86% |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
make legal judgments, approve deviations, negotiate sensitive terms, and manage privilege. That sentence drives the architecture. Every step the model can do safely, it does. Every step that requires judgment routes to a named human owner with a logged decision. For pharmaceuticals workflows where the risk includes medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails, this is the line between a demo and a defensible production system.
What we build inside the workflow
What makes contract review survive its first production quarter in pharmaceuticals is not the prompt — it is the surrounding scaffolding. We allocate at least 40% of the Build budget to non-model engineering: data access, source curation, eval harness, reviewer UI, audit logging. Counterintuitive on a "prompt engineering" timeline, but it is the only configuration where the workflow holds up past month three.
Reference architecture
4-layer AI-native workflow for risk & compliance
Source intake → AI orchestration → Action → Human review & quality.See the full architecture diagram for Risk & Compliance →
AI-native vs traditional approach
How a scoped AI-native engagement compares to the traditional alternatives for contract review in pharmaceuticals.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time to production | 6-12 months | 6-10 weeks (thin slice) |
| Pricing model | FTE hourly retainer or fixed staffing | Phased fixed-price (Discovery → Build → opt Run) |
| Audit / governance | Manual logs, periodic review | Versioned prompts, audit logs, reviewer queues, attestations |
| Operator throughput lift | 1.0× (baseline) | +38 pts |
| Cost per unit | Industry baseline | AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting. |
| Exit path | Multi-quarter notice + knowledge loss | Month-to-month Run, full handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
We run this as a fixed-scope engagement with a clear commercial envelope, not an open-ended retainer.
Governed engagement
Three phases, billed separately. You commit one phase at a time.
Phase 1 · Discovery
$8k
2-3 week sprint
Phase 2 · Build
$30k–$40k
8-12 weeks
Phase 3 · Run
$4k–$6k / mo
optional, quarterly attestations available
~$52k–$90k typical year 1 (~80% take the run option, regulated workflows need ongoing controls)
Controls, audit logs, reviewer queues, versioned prompts, and quarterly risk attestations.
Discovery is the only commitment to start. After Discovery, we scope Build with a fixed price. Run is opt-in, month-to-month, no lock-in.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
We map the workflow, the systems, the decisions, and the baseline metrics. Output: a scoped statement of work.
Phase 2 · Weeks 2–4
Design
We design the operating model: data access, retrieval, prompts, review queues, controls, and the KPI dashboard.
Phase 3 · Weeks 4–8
Build
We ship a production thin slice on real data, with versioned prompts, evaluation harness, and human review.
Phase 4 · Weeks 8+
Run
We run the workflow with you weekly, expand into adjacent work, and report against baseline.
Interactive ROI calculator
Estimate your AI-native ROI for contract review
Reference inputs below are typical for pharmaceuticals teams in the risk compliance cluster. Adjust them to match your situation.
Projected
Current monthly cost
$57,000
AI-native monthly cost
$20,070
Annual savings
$443,160
65% cost reduction · ~656 operator-hours freed / month
Governance and risk controls
Governance fails in two predictable ways in pharmaceuticals: paper controls that nobody enforces at runtime, and runtime controls that nobody can document for auditors. We build for both audiences. Every guardrail is enforced in code, and every guardrail is documented in the governance map with the line of code that implements it. The map and the code are kept in sync as part of the Run cadence.
How we report ROI
The ROI calculation we refuse to fudge on contract review is the time-to-value curve. Most pharmaceuticals AI projects report ROI on cherry-picked metrics at quarter-end. We report against a baseline captured in Discovery, on a fixed metric defined before Build, with the methodology documented in the Statement of Work. Boring, defensible, repeatable.
Common pitfall & mitigation
The failure mode we see most often on AI-native contract review engagements in pharmaceuticals contexts.
Reviewer queue overflow
Volume spikes during incident windows; reviewers can't keep SLA, escalations stack
Confidence threshold raised dynamically during volume spikes; secondary reviewer pool on retainer
Build internally or work with us
The build-vs-buy decision in pharmaceuticals usually comes down to four constraints: do you have AI engineering capacity, do you have ops capacity to govern it, do you have time-to-value pressure, and do you have a reference architecture to copy. We bring all four to an engagement. If you have two or fewer, working with us is faster and cheaper than building.
What to ask us before signing
- Ask for a workflow map that shows intake, retrieval, generation, review, escalation, system updates, and measurement.
- Ask for an evaluation plan using real examples from pharmaceuticals, not only generic test prompts.
- Ask how we will move review cycle time, fallback usage, negotiation rounds, and contract leakage within the first 30 to 60 days.
- Ask which parts of the process remain human-owned and why.
- Ask for our exit plan: what stays with you if the engagement ends.
Recommended first project
The best first project for AI-native contract review in pharmaceuticals is a contained workflow with enough volume to matter and enough structure to evaluate. Avoid the most politically sensitive process first. Avoid a workflow with no measurable baseline. Choose a process where we can ship a production-grade thin slice, prove adoption, and then extend the same architecture to neighboring work.
A practical target is a 30-day build followed by a 60-day operating period. In the first 30 days, we map the work, connect the minimum data sources, build the assistant, and create the review process. In the next 60 days, the system handles real volume, the team measures outcomes, and we improve the workflow weekly. By day 90, leadership knows whether to expand into adjacent work.
Frequently asked questions
How do you automate contract review in pharmaceuticals with AI?+
We map the existing contract review workflow inside pharmaceuticals, identify the high-volume, high-structure tasks, and build an AI agent that handles those tasks while routing low-confidence cases to a human reviewer. The build connects to your CRM, medical information systems, safety databases, runs against a labelled test set, and ships behind a reviewer queue before it sees production traffic. We then operate it, measure review cycle time, fallback usage, negotiation rounds, and contract leakage, and improve it weekly.
What does it cost to automate contract review for a pharmaceuticals company?+
Three phases, billed separately. Discovery sprint: $8k (2-3 week sprint). Build engagement: $30k–$40k (8-12 weeks). Run retainer: $4k–$6k / mo (optional, quarterly attestations available). ~$52k–$90k typical year 1 (~80% take the run option, regulated workflows need ongoing controls). Controls, audit logs, reviewer queues, versioned prompts, and quarterly risk attestations.
What is the best AI agent for contract review in pharmaceuticals?+
There is no single "best" off-the-shelf agent for contract review in pharmaceuticals — the right architecture depends on your CRM setup, your data, and your risk profile. We typically combine a frontier LLM (Claude, GPT-4-class, or Gemini) with a retrieval layer over your approved sources, tool-use for CRM and medical information systems integrations, and a reviewer queue. We benchmark candidate models against a labelled test set during Discovery and pick the one with the best accuracy/cost ratio for your workflow.
How long does it take to deploy AI contract review for pharmaceuticals?+
A thin-slice deployment in 2-3 week sprint after Discovery, with real pharmaceuticals data and real reviewers. The full Build phase runs 8-12 weeks. By day 90, review cycle time, fallback usage, negotiation rounds, and contract leakage is instrumented, the team has a baseline, and leadership has the data needed to decide on expansion into adjacent pharmaceuticals workflows.
What do we own, and what do you own?+
We own the workflow design, the prompts, the retrieval architecture, the evaluation harness, and weekly improvement. Your pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams team owns data access, policy, exception approval, and final commercial decisions. At the end of the engagement, every prompt, eval, and config is handed over — no lock-in.
How do you handle risk and audit for AI contract review in pharmaceuticals?+
Every output is grounded in approved sources, every prompt is versioned, and every reviewer action is logged. We provide a control map covering medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails, plus quarterly attestations on request.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on pharmaceuticals engagements. Cited here so you can verify and dig deeper.
- FDA Artificial Intelligence
- Responsible Scaling Policy — Anthropic
- AI Index Report — Stanford HAI
- Model Risk Management Handbook — Federal Reserve (SR 11-7)
- Principles for the Sound Management of AI Risks — BIS Financial Stability Institute
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Concepts on this page:
AI governance·NIST AI RMF·Audit log·Grounding·Guardrails·Model cardFull glossary →Start the engagement
Book a discovery call for Pharmaceuticals
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.